Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Bioactive Materials
|
December 6, 2024
Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches
Carmine D'Amico, Manlio Fusciello, Firas Hamdan, et al.
Materials Today. Bio
|
April 2, 2026
Corrigendum to 'Design and <i>in vitro</i> validation of Brome mosaic -virus-like particles for gene delivery and immunomodulation of melanoma' [Mater. Today Bio <b>36</b>, February 2026, 102693, https://doi.org/10.1016/j.mtbio.2025.102693]
Khalil Elbadri, Manlio Fusciello, Firas Hamdan, et al.
Cancer Immunology Research
|
September 25, 2021
β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection
Carla Guenther, Imrul Faisal, Manlio Fusciello, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 15, 2018
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, et al.
ACS Nano
|
May 18, 2019
Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
Flavia Fontana, Manlio Fusciello, Christianne Groeneveldt, et al.
Molecular Therapy. Oncology
|
April 10, 2024
Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy
Salvatore Russo, Sara Feola, Michaela Feodoroff, et al.
Journal for Immunotherapy of Cancer
|
March 8, 2024
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors
Sara Feola, Firas Hamdan, Salvatore Russo, et al.
Oncoimmunology
|
June 25, 2024
Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses
Heidi Harjunpää, Riku Somermäki, Guillem Saldo Rubio, et al.
Frontiers in Immunology
|
May 2, 2022
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
Sara Feola, Salvatore Russo, Beatriz Martins, et al.
Molecular Therapy Oncolytics
|
March 15, 2021
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform
Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Bioactive Materials
|
December 6, 2024
Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches
Carmine D'Amico, Manlio Fusciello, Firas Hamdan, et al.
Materials Today. Bio
|
April 2, 2026
Corrigendum to 'Design and <i>in vitro</i> validation of Brome mosaic -virus-like particles for gene delivery and immunomodulation of melanoma' [Mater. Today Bio <b>36</b>, February 2026, 102693, https://doi.org/10.1016/j.mtbio.2025.102693]
Khalil Elbadri, Manlio Fusciello, Firas Hamdan, et al.
Cancer Immunology Research
|
September 25, 2021
β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection
Carla Guenther, Imrul Faisal, Manlio Fusciello, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 15, 2018
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, et al.
ACS Nano
|
May 18, 2019
Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
Flavia Fontana, Manlio Fusciello, Christianne Groeneveldt, et al.
Molecular Therapy. Oncology
|
April 10, 2024
Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy
Salvatore Russo, Sara Feola, Michaela Feodoroff, et al.
Journal for Immunotherapy of Cancer
|
March 8, 2024
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors
Sara Feola, Firas Hamdan, Salvatore Russo, et al.
Oncoimmunology
|
June 25, 2024
Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses
Heidi Harjunpää, Riku Somermäki, Guillem Saldo Rubio, et al.
Frontiers in Immunology
|
May 2, 2022
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
Sara Feola, Salvatore Russo, Beatriz Martins, et al.
Molecular Therapy Oncolytics
|
March 15, 2021
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform
Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, et al.
Page
of 4